JAC Advance Access published online on January 30, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl005
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Discovery Research Laboratories II, Sumitomo Pharmaceuticals Research Division, 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka 554-0022, Japan; Present address: Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka 554-0022, Japan
* To whom correspondence should be addressed. Objectives: The aim of this study was to evaluate the efficacy and tissue concentration of AmBisome and Fungizone in murine pulmonary aspergillosis, and to investigate the localization of AmBisome at the infection site. Methods: Mice were infected intratracheally with Aspergillus fumigatus. A single dose of each of the antifungals was administered intravenously 4 h after infection. The efficacy of the antifungal treatment was assessed by the pulmonary fungal burden at 20 h post-treatment and the survival time over 1 month. The pulmonary amphotericin B (AMB) concentration was measured until 48 h after administration. The distribution of AmBisome in the lung was evaluated using rhodamine-labelled AmBisome and an anti-AMB antibody. Results: AmBisome at a dose of Conclusions: AmBisome is localized at the infection site in the lung and consequently may fully exhibit its in vivo activity. The efficacy of AmBisome is superior to that of Fungizone against pulmonary aspergillosis.
Received July 28, 2005
Revised November 8, 2005
Accepted December 23, 2005
Original article
Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis
Koji Takemoto 1 *,
Yutaka Yamamoto 2,
Yutaka Ueda 2,
Yoshihiro Sumita 2,
Koichiro Yoshida 3,
and
Yoshihito Niki 3
2 Discovery Research Laboratories II, Sumitomo Pharmaceuticals Research Division, 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka 554-0022, Japan
3 Division of Respiratory Disease, Department of Medicine, Kawasaki Medical School, 577, Matsushima, Kurashiki 701-0192, Japan
Koji Takemoto, E-mail: koji-takemoto{at}ds-pharma.co.jp
Abstract 
1 mg/kg significantly prolonged the survival time of infected mice compared with the control group. At the maximum tolerated dose, 10 mg/kg AmBisome exhibited greater efficacy than 1 mg/kg Fungizone in terms of increasing survival and reducing the fungal burden. The pulmonary AMB concentration of 10 mg/kg AmBisome was higher than that of 1 mg/kg Fungizone. Tissue distribution analysis showed that AmBisome was localized at the infection site in the lung, and this might explain the potent in vivo efficacy in this infection model.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Ellis, R. Bernsen, H. Ali-Zadeh, J. Kristensen, U. Hedstrom, L. Poughias, M. Bresnik, A. Al-Essa, and D. A. Stevens A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever J. Med. Microbiol., November 1, 2009; 58(11): 1474 - 1485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takazono, K. Izumikawa, T. Mihara, K. Kosai, T. Saijo, Y. Imamura, T. Miyazaki, M. Seki, H. Kakeya, Y. Yamamoto, et al. Efficacy of Combination Antifungal Therapy with Intraperitoneally Administered Micafungin and Aerosolized Liposomal Amphotericin B against Murine Invasive Pulmonary Aspergillosis Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3508 - 3510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Smith, J. A. Olson, D. Constable, J. Schwartz, R. T. Proffitt, and J. P. Adler-Moore Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B J. Antimicrob. Chemother., May 1, 2007; 59(5): 941 - 951. [Abstract] [Full Text] [PDF]
|
|